High Court OKs Patent Use Challenges By Generic Drug Cos.

Law360, New York (April 17, 2012, 1:06 PM EDT) -- The U.S. Supreme Court ruled Tuesday that a generic-drug maker can countersue to force a pharmaceutical patent-holder to correct a use code overstating a patent's scope, nixing an earlier decision in Caraco Pharmaceutical Laboratories Inc.'s fight with Novo Nordisk A/S that critics worried would thwart generic competition.

The justices unanimously rejected the Federal Circuit's narrower reading of a provision of the Hatch-Waxman Act that set up a counterclaim allowing generics makers to challenge the patent information that brand drugmakers provide the U.S. Food and Drug Administration....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.